-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Himalaya Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development and commercialization of new experimental antibody therapies for the treatment of solid tumor cancer based on the Conditional Active Biotechnology (CAB) technology platform in Greater China, today announced the appointment of Nicholas Desjardins ( Deng Ning) is the Chief Financial Officer and Corporate Development Officer
.
In this position, he will lead Himalaya's finance and accounting functions, and will be responsible for investor relations and corporate communications
Carolyn Short, co-founder of Himalaya Therapeutics and president since its establishment in 2014, said: "Dunning brings Himalaya the unique combined experience of China and the United States in finance, operations and biotechnology.
We believe this will become the Himalaya team.
An important advantage
.
Dunning is the first new executive in a series of new recruits that we plan to expand our development activities in the Greater China region.
Dunning has 15 years of investment banking experience mainly in the field of biotechnology, including helping multiple companies and raising more than $1.
4 billion in 17 IPOs in Cowen and Stifel, and in nearly 50 other strategic transactions and capital financings Another 9.
1 billion USD was raised
.
Recently, he led the consulting business of professional merchant bank ASGARD Partners
"I am very excited to join the company at this important juncture in Himalaya's development trajectory.
Our main drug candidate enters Phase 2 clinical trials in Greater China, which will help achieve the milestone of continuing to create value for shareholders
.
I look forward to working with us.
